A clinically approved inhibitor of glycosphingolipid biosynthesis, N-butyldeoxynojirimycin, normalized CD4+ T cell functions and decreased anti-dsDNA antibody production by autologous B cells in SLE patients [130]. This evidence concerns the gene CD4 and systemic lupus erythematosus.